𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Etanercept in Sjögren's syndrome: a pilot-randomized, double-blind, placebo-controlled clinical trial

✍ Scribed by V Sankar; M.T Brennan; M.R Kok; R.A Leakan; J.A Smith; J Manny; B.J Baum; S.R Pillemer

Book ID
116940569
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
43 KB
Volume
97
Category
Article
ISSN
1528-395X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Etanercept in Sjögren's syndrome: A twel
Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial
✍ Vidya Sankar; Michael T. Brennan; Marc R. Kok; Rose Anne Leakan; Janine A. Smith 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract ## Objective To assess the safety and potential efficacy of etanercept in the treatment of Sjögren's syndrome (SS). ## Methods This pilot study was a 12‐week randomized, double‐blind, placebo‐controlled trial of etanercept, with 14 subjects in each group. Patients received 25 mg of e

Pilot clinical trial of dehydroepiandros
Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome
✍ Pillemer, Stanley R. ;Brennan, Michael T. ;Sankar, Vidya ;Leakan, Rose Anne ;Smi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB 👁 1 views

## Abstract ## Objective To screen for potential efficacy and assess feasibility and safety of dehydroepiandrosterone (DHEA) as a treatment for Sjögren's syndrome (SS). ## Methods A 24‐week randomized, double‐blinded, pilot trial of oral DHEA (200 mg/day) versus placebo was conducted. The primar

Randomized, placebo-controlled, double-b
Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease
✍ Andrea Martinuzzi; Alexandra Liava; Enrico Trevisi; Mara Frare; Caterina Tonon; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

## Abstract McArdle's disease causes limitation in exercise capacity as well as disability, the severity of which has been associated with the angiotensin‐converting enzyme (ACE) insertion (I)/deletion (D) haplotype—patients with the genotype associated with higher ACE activity show the most severe